Loading [MathJax]/jax/output/SVG/jax.js
Review Special Issues

Bacteriophages—a new hope or a huge problem in the food industry

  • Bacteriophages are viruses that are ubiquitous in nature and infect only bacterial cells. These organisms are characterized by high specificity, an important feature that enables their use in the food industry. Phages are applied in three sectors in the food industry: primary production, biosanitization, and biopreservation. In biosanitization, phages or the enzymes that they produce are mainly used to prevent the formation of biofilms on the surface of equipment used in the production facilities. In the case of biopreservation, phages are used to extend the shelf life of products by combating pathogenic bacteria that spoil the food. Although phages are beneficial in controlling the food quality, they also have negative effects. For instance, the natural ability of phages that are specific to lactic acid bacteria to destroy the starter cultures in dairy production incurs huge financial losses to the dairy industry. In this paper, we discuss how bacteriophages can be either an effective weapon in the fight against bacteria or a bane negatively affecting the quality of food products depending on the type of industry they are used.

    Citation: Marzena Połaska, Barbara Sokołowska. Bacteriophages—a new hope or a huge problem in the food industry[J]. AIMS Microbiology, 2019, 5(4): 324-346. doi: 10.3934/microbiol.2019.4.324

    Related Papers:

    [1] V. Flores-Alés, F.J. Alejandre, F.J. Blasco-López, M. Torres-González, J.M. Alducin-Ochoa . Analysis of alterations presented in a white-concrete façade exposed to a marine environment——A case study in Cádiz (Spain). AIMS Materials Science, 2022, 9(2): 255-269. doi: 10.3934/matersci.2022015
    [2] Grzegorz Ludwik Golewski . Mechanical properties and brittleness of concrete made by combined fly ash, silica fume and nanosilica with ordinary Portland cement. AIMS Materials Science, 2023, 10(3): 390-404. doi: 10.3934/matersci.2023021
    [3] Tayebi M'hammed, Khelafi Hamid . An experimental study on the influence of arid climate on early-age cracking of concrete—A case study of the city of Adrar in Algeria. AIMS Materials Science, 2021, 8(2): 200-220. doi: 10.3934/matersci.2021014
    [4] M. Kanta Rao, Ch. N. Satish Kumar . Influence of fly ash on hydration compounds of high-volume fly ash concrete. AIMS Materials Science, 2021, 8(2): 301-320. doi: 10.3934/matersci.2021020
    [5] Mahmoud A. Rabah, Mohamed B. El Anadolly, Rabab A. El Shereif, Mohamed Sh. Atrees, Hayat M. El Agamy . Preparation of valuable products from cleaned carbon of fuel ash. AIMS Materials Science, 2017, 4(5): 1186-1201. doi: 10.3934/matersci.2017.5.1186
    [6] Aleksei V. Shiverskii, Aleksandr V. Kukharskii, Stepan V. Lomov, Sergey G. Abaimov . Recycling glass fiber-reinforced plastic in asphalt concrete production. AIMS Materials Science, 2024, 11(2): 231-242. doi: 10.3934/matersci.2024013
    [7] Ayumu Yasue, Keita Hayashi, Shogo Yamamoto, Toshitsugu Inukai, Shigeru Fujimori . Influence of concrete bleeding due to mix proportion on the drilling speed of hardened surface layer. AIMS Materials Science, 2021, 8(3): 486-500. doi: 10.3934/matersci.2021030
    [8] Yustina M Pusparizkita, Vivi A. Fardilah, Christian Aslan, J. Jamari, Athanasius P Bayuseno . Understanding of low-carbon steel marine corrosion through simulation in artificial seawater. AIMS Materials Science, 2023, 10(3): 499-516. doi: 10.3934/matersci.2023028
    [9] M. P. Lavin-Lopez, L. Sanchez-Silva, J. L. Valverde, A. Romero . CVD-graphene growth on different polycrystalline transition metals. AIMS Materials Science, 2017, 4(1): 194-208. doi: 10.3934/matersci.2017.1.194
    [10] Stelladriana Volpe, Andrea Petrella, Valentino Sangiorgio, Michele Notarnicola, Francesco Fiorito . Preparation and characterization of novel environmentally sustainable mortars based on magnesium potassium phosphate cement for additive manufacturing. AIMS Materials Science, 2021, 8(4): 640-658. doi: 10.3934/matersci.2021039
  • Bacteriophages are viruses that are ubiquitous in nature and infect only bacterial cells. These organisms are characterized by high specificity, an important feature that enables their use in the food industry. Phages are applied in three sectors in the food industry: primary production, biosanitization, and biopreservation. In biosanitization, phages or the enzymes that they produce are mainly used to prevent the formation of biofilms on the surface of equipment used in the production facilities. In the case of biopreservation, phages are used to extend the shelf life of products by combating pathogenic bacteria that spoil the food. Although phages are beneficial in controlling the food quality, they also have negative effects. For instance, the natural ability of phages that are specific to lactic acid bacteria to destroy the starter cultures in dairy production incurs huge financial losses to the dairy industry. In this paper, we discuss how bacteriophages can be either an effective weapon in the fight against bacteria or a bane negatively affecting the quality of food products depending on the type of industry they are used.


    Appropriate mathematical models of infectious diseases are helpful to reveal the mechanism of disease transmission and to predict the final scale of the epidemic [1]. The social contact network of a population plays a significant role in controlling the propagation of infectious diseases [2,3]. However, directly analyze the propagation of disease on stochastic contact networks is very difficult, one often relies on deterministic mean-field models that are aimed at approximating some average quantities derived from the stochastic models [4,5,6,7].

    Based on the probability generating function for the degree distribution on a contact network, Volz introduced an edge-based SIR epidemic model, which has the great advantage of having a system with only three differential equations [8]. This method describes the SIR disease spread process with heterogeneous connectivity by the contact network structure. Its core is to track the change of the probability that the neighboring nodes around the susceptible nodes are infected. Furthermore, Miller derived a single differential equation with only a single higher order term that governs the dynamics of the disease [9]. Recently, using the EBCM approach for the spread of susceptible-infected-recovered (SIR) diseases in contact networks, Miller et al. [10] derived some simple ordinary differential equation models capturing social heterogeneity and heterogeneous contact rates while explicitly considering the impact of partnership duration. However, the theoretical analysis of such models is usually difficult, and their validity is usually demonstrated through numerical simulations. For an edge-based epidemic model with large initial value, Miller [11] obtained the threshold of disease transmission and the final infection size. Using the same method, in a recent paper[12], we established a sexually transmitted disease model on a bidirectional contact network with large initial value and analyzed in detail the global dynamics of the model. We refer the reader to references [13,15,14,16] and references therein for related works in this direction.

    Vaccination in disease control strategies generally reduces the susceptibility of a node of network, but could either increase or decrease the infectiousness of a node by reducing the severity of symptoms. Modelling a disease with heterogeneous infectiousness and susceptibility in stochastic contact network can be seen in [17,18]. Using the EBCM technique, in a recent paper [19], Miller and Volz proposed an SIR model considering the heterogeneous susceptibility and infectiousness of individuals. Assume $ i $ is a parameter measuring a node's ability to become infected and cause infection, but that is does not influence the contact structure of the population. Without loss of generality, we assume that the population is divided into $ M $ types. The model proposed in [19] takes the following form:

    $ dθi,jdt=(βi,j+γj)θi,j+βi,jψ(˜θj)ψ(1)+γj,  i,j=1,2,,M,Si=ψ(˜θi),   dRidt=γiIi,   Ii=1SiRi,S=Mi=1SiQ(i),   I=Mi=1IiQ(i),  R=Mi=1RiQ(i), $ (1)

    with initial value $ \theta_{i, j}(0) = 1 $ and $ I(0) = R(0) = 0 $, where $ \tilde{\theta}_j = \sum_{l = 1}^M\theta_{j, l} \mathcal {Q}(l) $. The variables and parameters in model (1) are summarized in Table 1. For this model, the authors provided a numerical example to confirm its validity [19]. Here, we investigate the dynamics of the model (1) through mathematical analysis.

    Table 1.  The variables and parameters used in the derivation of model (1). In these $ u $ is a test individual: Randomly chosen from the population and modified so that it cannot infect other individuals, although it can become infected.
    Variable/parameter Definition
    $ u $ A randomly chosen node prevented from transmitting to its partners.
    $ S/I/R $ The probability that $ u $ is susceptible/infected/recovered at time $ t $.
    $ S_i/I_i/R_i $ The proportion of type-$ i $ nodes who are susceptible/infected/recovered at time $ t $.
    $ \mathcal {Q}(j) $ The probability $ u $ is of type $ j $.
    $ \theta_{i, j} $ The probability that an edge from a type-$ j $ partner $ v $ to the test node $ u $ of type $ i $ has not transmitted infection from $ v $ to $ u $.
    $ \tilde{\theta}_j=\sum_l\theta_{j, l}\mathcal {Q}(l) $ The probability that a random edge to $ u $ of type $ j $ has not transmitted infection to $ u $.
    $ \phi_{S: i, j} $ The probability that the partner $ v $ of a $ \theta_{i, j} $ edge is susceptible.
    $ \phi_{I: i, j} $/$ \phi_{R: i, j} $ The probability that the partner $ v $ of a $ \theta_{i, j} $ edge is infected/recovered but the edge has not transmitted.
    $ P(k) $ The probability that a randomly chosen node has degree $ k $.
    $ \psi(x)=\sum_k P(k)x^k $ The probability generating function of degree distribution $ P(k) $.
    $ \psi'(\tilde{\theta}_j) $ The derived function of the probability generating function about $ \tilde{\theta}_j $.
    $ \psi'(1) $ The average degree of contact network.
    $ \beta_{i, j} $ The transmission rate from a type-$ j $ infected node to a type-$ i $ node.
    $ \gamma_j $ The recovery rate of a type-$ j $ infected node.

     | Show Table
    DownLoad: CSV

    The organization of this paper is as follows. In the next section, we recall the derivation process of model (1), then we present our main results, including the derivation of the final size of an epidemic. In section 3, we provide the detailed proof of our main theorem. Finally, in section 4, we provide two simple scenarios for the special cases when $ M = 1 $ and $ M = 2 $ to make our results easier to understand.

    In this section, we recall the derivation process of model (1), then we present our main results.

    Assume the network structure is unchanged, that is the degree distribution $ P(k) $ of the network is fixed. The nodes of the network are classified into $ M $ types according to their ability to become infected and cause infection. Now randomly choose a test node $ u $ from the network, and assume that the probability it is of type $ i $ is $ \mathcal{Q}(i) $, then $ \sum_{i = 1}^M\mathcal{Q}(i) = 1 $. It is easy to deduce the probability that the test node $ u $ is susceptible, infected or recovered. In fact,

    $ S=Mi=1SiQ(i),   I=Mi=1IiQ(i),  R=Mi=1RiQ(i), $

    where $ S_i $, $ I_i $ and $ R_i $ are respectively the probabilities that a type-$ i $ node is susceptible, infected and recovered at time $ t $, and therefore

    $ Si+Ii+Ri=1. $ (2)

    Let $ \theta_{i, j} $ denote the probability that an edge from a type-$ j $ partner $ v $ to the test node $ u $ of type-$ i $ has not transmitted infection from $ v $ to $ u $, and let $ \phi_{S:i, j} $ be the probability $ v $ is still susceptible, $ \phi_{I:i, j} $ the probability $ v $ is infected but the edge has not transmitted, and $ \phi_{R:i, j} $ the probability that $ v $ has recovered without transmitting. Then $ \theta_{i, j} = \phi_{S:i, j}+\phi_{I:i, j}+\phi_{R:i, j} $, and therefore,

    $ ϕI:i,j=θi,jϕS:i,jϕR:i,j. $ (3)

    Define $ \tilde{\theta}_i $ as the probability that a random edge to a type-$ i $ node $ u $ has not transmitted infection to $ u $, then $ \tilde{\theta}_i = \sum_{j = 1}^M\theta_{i, j} \mathcal {Q}(j) $, and therefore,

    $ Si=Mk=1P(k)˜θki=ψ(˜θi) $ (4)

    and

    $ ϕS:i,j=Mk=1kP(k)Ml=1lP(l)˜θk1j=ψ(˜θj)ψ(1), $ (5)

    where $ \psi(x) = \sum_k P(k)x^k $ is the probability generating function of degree distribution $ P(k) $. The transmission rate $ \beta_{i, j} $ from a type-$ j $ node to a type-$ i $ node and the recovery rate $ \gamma_i $ of a type-$ i $ node are type dependent, and they are assumed to be positive. From the probability fluxes between $ S_i $, $ I_i $ and $ R_i $ compartments (upper) and those between $ \phi_{S:i, j} $, $ \phi_{I:i, j} $ and $ \phi_{R:i.j} $ (lower) as shown in Figure 1, we have that

    $ dRidt=γiIi,  dϕR:i,jdt=γjϕI:i,j,  dθi,jdt=βi,jϕI:i,j. $ (6)
    Figure 1.  Flow diagram for an SIR network model with heterogeneous infectiousness and susceptibility. The nodes are separated into $ M $ types by type $ i $, but assume that $ i $ has no effect on connectivity. Both infectiousness and susceptibility may depend on $ i $.

    We can derive from the last two equations in Eq (6) with initial value

    $ \phi_{I:i, j}(0) = \phi_{R:i, j}(0) = 0 $

    that $ \phi_{R_{i, j}} = \frac{\gamma_j}{\beta_{i, j}}(1-\theta_{i, j}) $. Combining Eqs (3) and (5) and the second equation of $ \phi_{R:i, j} $ in Eq (6), we then derive system (7) from the last equation of $ \theta_{i, j} $ in Eq (6) (see [19] for more details). Thus, the whole dynamics of the disease transmission are summarized by model (1).

    Notice that the dynamics of model (1) is determined by the dynamics of the following subsystem:

    $ dθi,jdt=(βi,j+γj)θi,j+βi,jψ(˜θj)ψ(1)+γj:=Fi,j(θ), $ (7)

    where $ i, j = 1, 2, \ldots, M $. Define

    $ Ω={θ=(θ1,1,θ1,2,,θ1,M,θ2,1,,θM,M): 0θi,j1, i,j=1,2,,M}. $

    Then $ \Omega $ is a positive invariant set of system (7). We only need to consider the dynamics of system (7) constrained in $ \Omega $. Notice that system (7) always contains the disease free equilibrium $ E_0 = (1, 1, \dots, 1, 1, \ldots, 1) $.

    Let $ D_{\theta}F(\theta) = (D_{\theta}F_{i, j})(\theta) $ be the jacobian matrix of system (7), where

    $ F(θ)=(F1,1,F1,2,,F1,M,F2,1,,FM,M)(θ), $

    and denote

    $ ρ0=max{(λ):λis the eigenvalue of matrixDθF(E0)}, $ (8)

    where $ D_{\theta}F(E_0) $ is the jacobian matrix $ D_{\theta}F(\theta) $ at $ E_0 $. Our main result can be summarized in the following theorem.

    Theorem 2.1. System (7) has at most two equilibria in the region $ \Omega $. Moreover,

    (a) When $ \rho_0 < 0 $, then the system has only the disease free equilibrium

    $ E_0 = (1, 1, ... , 1, 1, ... , 1) $

    which is globally asymptotically stable in $ \Omega $.

    (b) When $ \rho_0 > 0 $, then the disease free equilibrium $ E_0 $ becomes unstable, and another outbreak equilibrium

    $ E=(θ()1,1,θ()1,2,...,θ()1,M, θ()2,1, ...,θ()M,M)Int Ω $

    appears which is globally asymptotically stable in the region $ \Omega\setminus\{E_0\} $.

    Remark 1. Based on Theorem Theorem 2.1, we know from model (1) that if $ \rho_0 > 0 $, then after the epidemic is over, the fraction of individuals who have never been infected is

    $ S()=Mi=1Si()Q(i)=Mi=1ψ(˜θ()i)Q(i), $

    where $ \tilde{\theta}_i^{(*)} = \sum_{j = 1}^M\theta_{i, j}^{(*)}\mathcal {Q}(j) $. Thus, the final size of an epidemic in the population is

    $ Z=1S()=1Mi=1ψ(˜θ()i)Q(i). $

    We first introduce the following lemma which is used in the proof of our main theorem.

    Lemma 3.1 ([20]). For system $ \frac{d}{dt} x = F(x) $, let F(x) be a $ C^1 $ cooperative vector field in $ R^n $, whose flow $ \phi $ preserves $ R_+^n $ for $ t\geq0 $ and is irreducible in $ R_+^n $. Assume that the origin is an equilibrium and that all trajectories in $ R_+^n $ are bounded. Suppose the matrix-valued map $ DF $: $ R^n\rightarrow R^{n\times n} $ is strictly antimonotone, in the sense that if $ x > y $, then $ DF(x) < $DF(y). Then either all trajectories in $ R_+^n $ tend to the origin, or else there is a unique equilibrium $ p\in \text{Int}\ R_+^n $ and all trajectories in $ R_+^n\setminus \{0\} $ tend to $ p $.

    Proof. The jacobian matrix $ D_{\theta}F(\theta) $ of system (7) is

    $ DθF(θ)=(D1,11,1D1,11,2...D1,11,MD1,12,1...D1,1M,MD1,21,1D1,21,2...D1,21,MD1,22,1...D1,2M,MD1,31,1D1,31,2...D1,31,MD1,32,1...D1,3M,M.....................DM,M1,1DM,M1,2...DM,M1,MDM,M2,1...DM,MM,M), $ (9)

    where $ i, \ j, \ l, \ m = 1, 2\ldots, M $, and when $ i = l $,

    $ Di,jl,m=Di,ji,m=Fi,jθi,m={(βi,i+γi)+βi,iψ(˜θi)ψ(1)Qi,  m=i,βi,iψ(˜θi)ψ(1)Ql,mi}=Fi,iθi,l,   i=j,(βi,j+γj),   m=j,0,   mj},    ij, $

    when $ i\neq l $,

    $ Di,jl,m=Fi,jθl,m={βi,jψ(˜θj)ψ(1)Qm,   l=j,0,lj. $

    The off-diagonal elements of $ D_{\theta}F(\theta) $ are non-negative, and it is easy to check that $ D_{\theta}F(\theta) $ is strongly connected* when $ \beta_{i, j} > 0 $. Thus, system (7) is a irreducible cooperative system in $ \Omega $ [20]. Consequently, when $ \rho_0 < 0 $, the equilibrium $ E_0 $ is locally asymptotically stable, and when $\rho_0>$0, the equilibrium $E_0$ is unstable.

    *The definition of strongly connected and irreducible cooperative systems, refer to [20].

    To prove the global results of system (7) in $ \Omega $ applying Lemma 3.1, we make the coordinate transformation $ \vartheta_{i, j} = 1-\theta_{i, j} $, under which system (7) becomes

    $ dϑi,jdt=(βi,j+γj)ϑi,jβi,jψ(˜ϑj)ψ(1)+βi,j:=Fi,j(ϑ), $ (10)

    where $ i, j = 1, 2, \cdots, M $, and $ \tilde{\vartheta}_j = \sum_{l = 1}^M(1-\vartheta_{j, l})\mathcal {Q}(l) = 1-\sum_{l = 1}^M\vartheta_{j, l}\mathcal {Q}(l) $. Notice that $ \Omega $ is still the positive invariant set of system (10), and the disease free equilibrium $ E_0 $ is now transformed into the zero equilibrium $ \mathscr{E}_0 $ of system (10), where

    $ E0=(ϑ1,1, ϑ1,2, ..., ϑ1,M, ϑ2,1, ..., ϑM,M)=(0, 0,..., 0, 0, ..., 0). $

    Denote $ \mathcal {F}(\vartheta) = (\mathcal {F}_{1, 1}, \mathcal {F}_{1, 2}, \cdots, \mathcal {F}_{1, M}, \mathcal {F}_{2, 1}, \cdots, \mathcal {F}_{M, M})(\vartheta) $. Noticing that $ \mathcal{F}(\vartheta) = -F(1_{M^2}-\vartheta) $, we can deduce that

    $ DϑF(E0)=DθF(E0), $

    where $ D_{\vartheta}\mathcal{F}(\mathscr{E}_0) $ is the jacobian matrix $ D_{\vartheta}\mathcal{F}(\vartheta) $ of system (10) at $ \mathscr{E}_0 $. Moreover, from Lemma 3.1 we know that $ \mathscr{E}_0 $ is locally asymptotically stable when $ \rho(D_{\theta}F(E_0))\leq 0 $, and unstable when $ \rho(D_{\theta}(E_0)) > 0 $.

    We first consider the global stability results of system (10). Notice the following:

    (a) System (10) is still an irreducible cooperative system in the bounded region $ \Omega $ as

    $ DϑF(ϑ)=DθF(θ)|θ=1M2ϑDϑ(1M2ϑ)=DθF(θ)|θ=1M2ϑ. $

    (b) $ D_{\vartheta}\mathcal {F}(\vartheta) $ is strictly antimonotone in $ \Omega $. Since $ \psi(\tilde{\theta}_i) $ and $ \psi''(\tilde{\theta}_i) $ are both monotone increasing functions with respect to $ \theta_{i, j} $ in the bounded region $ \Omega $, and therefore both $ \psi(\tilde{\vartheta}_i) $ and $ \psi''(\tilde{\vartheta}_i) $ are monotone decreasing functions of $ \vartheta_{i, j} $ in $ \Omega $ due to the relationship $ \tilde{\vartheta}_i = 1-\sum_{j = 1}^M\vartheta_{i, j}\mathcal {Q}(j) $. By comparison, we can check that when $ \vartheta_1 < \vartheta_2 $, we have $ D_{\vartheta}\mathcal {F}(\vartheta_1) > D_{\vartheta}\mathcal {F}(\vartheta_2) $.

    According to Lemma 3.1, either all trajectories in $ \Omega $ tend to the zero equilibrium $ \mathscr{E}_0 $ of system (10), or else there is a unique equilibrium

    $ E=(ϑ()1,1, ϑ()1,2, , ϑ()1,M, ϑ()2,1, , ϑ()M,M)Int Ω $

    and all trajectories in $ \Omega\setminus\mathscr{E}_0 $ tend to $ \mathscr{E}_* $. These, together with the local stability results of $ \mathscr{E}_0 $, indicates that when $ \rho_0 < 0 $, $ \mathscr{E}_0 $ is globally asymptotically stable in $ \Omega $, and when $ \rho_0 > 0 $, it becomes unstable and the equilibrium $ \mathscr{E}_* $ is globally asymptotically stable in $ \Omega\setminus\mathscr{E}_0 $.

    Now let $ E_* = 1_{M^2}-\mathscr{E}_* $, then $ E_*\in \text{Int}\ \Omega $ is the unique outbreak equilibrium of system (7). Based on the arguments above, we deduce that when $ \rho_0 < 0 $, $ E_0 $ is globally asymptotically stable in $ \Omega $, and when $ \rho_0 > 0 $, it becomes unstable and the outbreak equilibrium $ E_* $ is globally asymptotically stable in $ \Omega\setminus\mathscr{E}_0 $. The proof of Theorem Theorem 2.1 is thus completed.

    Remark 2. Theorem 2.1 provides a theoretical basis for the prevention and control of heterogeneous infectious and heterogeneous infectious diseases. For example, vaccination generally reduces the susceptibility of a node in community, then the population can be divided into those who have or have not received vaccination. The results of our analysis can be used to analyze the effectiveness of vaccination strategies.

    Scenario 4.1. In the special case when $ M = 1 $, i.e., there is only one type of node in contact network, system (7) is reduced to the model established in Miller [9]:

    $ dθ1,1dt=(β1,1+γ1)θ1,1+β1,1ψ(θ1,1)ψ(1)+γ1. $ (11)

    Here $ E_0 = (1) $ and $ \rho_0 = -(\beta_{1, 1}+\gamma_1)+\beta_{1, 1}\frac{\psi''(1)}{\psi'(1)} $. Moreover, $ \rho_0 = 0 $ can be equivalently written as $ \frac{\beta_{1, 1}}{(\beta_{1, 1}+\gamma_1)}\frac{\psi''(1)}{\psi'(1)} = 1 $. Define

    $ R0=β1,1(β1,1+γ1)ψ(1)ψ(1). $ (12)

    Then $ \mathcal{R}_0 $ is the basic reproduction number of the disease. Notice that $ \mathcal{R}_0\leq 1 $ if and only if $ \rho_0\leq 0 $. We have the following result.

    Corollary 1. System (11) has at most two equilibria in the region

    $ \Omega = \{\theta_{1, 1}: 0\leq \theta_{1, 1}\leq 1\}. $

    Moreover,

    (a) When $ \mathcal{R}_0 \leq 1 $, then the system has only the disease free equilibrium $ E_0 $ which is globally asymptotically stable in $ \Omega $.

    (b) When $ \mathcal{R}_0 > 1 $, then the disease free equilibrium $ E_0 $ is unstable, and the outbreak equilibrium $ E_* = (\theta_{1, 1}^{(*)})\in \text{Int} \Omega $ appears and it is globally asymptotically stable in the region $ \Omega\setminus\{E_0\} = \{\theta_{1, 1}: 0\leq \theta_{1, 1} < 1\} $.

    Proof. We only need to prove that when $ \mathcal{R}_0 = 1 $ (i.e., $ \rho_0 = 0 $), $ E_0 = (1)_{1\times 1} $ is globally asymptotically stable. In fact, denote

    $ F1,1(θ1,1)=(β1,1+γ1)θ1,1+β1,1ψ(θ1,1)ψ(1)+γ1. $

    We compute that

    $ dF1,1(θ1,1)dθ1,1=(β1,1+γ1)+β1,1ψ(θ1,1)ψ(1)<0 $

    for $ \theta_{1, 1}\in[0, 1) $ due to $ \rho_0 = 0 $. Thus, $ F_{1, 1}(\theta_{1, 1}) $ is strictly monotonically decreasing on the interval $ [0, 1] $ with $ F_{1, 1}(1) = 0 $ and therefore $ E_0 = (1) $ is the unique equilibrium of system (11). It then follows from $ \frac{ {\bf{d}}\theta_{1, 1}}{ {\bf{d}}t} > 0 $ that for any solution with initial value $ \theta_{1, 1}(0)\in [0, 1) $, $ E_0 $ is globally asymptotically stable in $ \Omega = [0, 1] $. The proof is thus completed.

    Scenario 4.2. In the special case when $ M = 2 $, i.e., there have two difference type of node in contact network, system (7) takes the form:

    $ {dθ1,1dt=(β1,1+γ1)θ1,1+β1,1ψ(˜θ1)ψ(1)+γ1:=F1,1(θ),dθ1,2dt=(β1,2+γ2)θ1,2+β1,2ψ(˜θ2)ψ(1)+γ2:=F1,2(θ),dθ2,1dt=(β2,1+γ1)θ2,1+β2,1ψ(˜θ1)ψ(1)+γ1:=F2,1(θ),dθ2,2dt=(β2,2+γ2)θ2,2+β2,2ψ(˜θ2)ψ(1)+γ2:=F2,2(θ). $ (13)

    Here $ E_0 = (1, \; 1, \; 1, \; 1) $. The jacobian matrix $ D_{\theta}F(\theta) $ of system (13) at $ E_0 $ is

    $ DθF(E0)=(1,1(1)β1,1ψ(1)ψ(1)Q(2)000(β1,2+γ2)β1,2ψ(1)ψ(1)Q(1)β1,2ψ(1)ψ(1)Q(2)β2,1ψ(1)ψ(1)Q(1)β2,1ψ(1)ψ(1)Q(2)(β2,1+γ1)000β2,2ψ(1)ψ(1)Q(1)2,2(1)), $

    where $ \triangle_{i, i}(1) = (\beta_{i, i}+\gamma_i)-\beta_{i, i}\frac{\psi''(1)}{\psi'(1)}\mathcal {Q}(i), \ i = 1, 2 $. Define $ \rho_0 $ as in Eq (8). We have the following result.

    Corollary 2. System (7) has at most two equilibria in the region

    $ \Omega = \{\theta_{i, j}:0\leq\theta_{i, j}\leq 1, \ i, j = 1, 2 \}. $

    Moreover,

    (a) When $ \rho_0 < 0 $, then the system has only the disease free equilibrium $ E_0 $ which is globally asymptotically stable in $ \Omega $.

    (b) When $ \rho_0 > 0 $, then the disease free equilibrium $ E_0 $ is unstable, and the outbreak equilibrium

    $ E=(θ()1,1,θ()1,2,θ()2,1,θ()2,2)Int Ω $

    appears and it is globally asymptotically stable in the region $ \Omega\setminus\{E_0\} $.

    Remark 3. From Scenario 1 we know that for the special case when $ M = 1 $, the disease free equilibrium $ E_0 = (1) $ is globally asymptotically stable (GAS) when $ \rho_0 = 0 $ (i.e., $ \mathcal{R}_0 = 1 $), but we can not prove that a similar result holds for the special case when $ M = 2 $. We guess the disease free equilibrium $ E_0 $ of model (1) is also GAS for all $ M\neq 1 $. We leave it as an open problem.

    Considering the fact that the individuals may have different susceptibility and infectiousness to the disease spreading in the population, in a recent paper [19], Miller and Volz proposed an SIR disease network model (i.e., model (1)) with heterogeneous infectiousness and susceptibility. The authors have provided a numerical example to demonstrate its validity but its mathematical analysis remain unsolved. In this paper, with the aid of the nature of irreducible cooperative system in the theory of monotonic dynamical system, we prove that the dynamics of the model are completely determined by a critical value $ \rho_0 $: When $ \rho_0 > 0 $, the disease persists in a globally stable outbreak equilibrium; while when $ \rho_0 < 0 $, the disease dies out in the population and the disease free equilibrium is globally stable.

    Notice that it is assumed that in model (1) the random network considered is statically fixed and does not take into account the influence of new nodes, deleted nodes and other factors on the network. This is an approximation of the reality. More proper and reasonable model should consider these facts and be based on dynamic random networks. Moreover, how to characterize the epidemic process of heterogeneous infectious networks through numerical simulation is also a challenging problem. We leave all these for our future consideration.

    Research is supported by the National Natural Science Foundation of China (No. 11671260).

    The authors declare there is no conflict of interest.


    Abbreviation LAB: lactic acid bacteria; DP: depolymerase enzyme; MRSA: methicillin-resistant ; EFSA: European Food Safety Authority; WHO: World Health Organization; FDA: Food and Drug Administration; RTE: ready to eat; EPS: extracellular polymeric substances;
    Acknowledgments



    This work was financially supported by Institute of Agricultural and Food Biotechnology, 36 Rakowiecka, 02-532 Warsaw, Poland.

    Conflict of interest



    All authors declare no conflicts of interest in this paper.

    [1] Hendrix WR (2002) Bacteriophages: evolution of the majority. Theor Popul Biol 61: 471–480. doi: 10.1006/tpbi.2002.1590
    [2] Hietala V, Horsma-Heikkinen J, Carron A, et al. (2019) The removal of endo- and enterotoxins from bacteriophage preparations. Front Microbiol 10: 1–9. doi: 10.3389/fmicb.2019.00001
    [3] Sarhan WA, Azzazy HM (2015) Phage approved in food, why not as a therapeutic? Expert Rev Anti Infect Ther 13: 91–101. doi: 10.1586/14787210.2015.990383
    [4] Górski A, Międzybrodzki R, Borysowski J, et al. (2012) Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83: 41–71. doi: 10.1016/B978-0-12-394438-2.00002-5
    [5] Wittebole X, Roock De S, Opa M (2014) Historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5: 226–235. doi: 10.4161/viru.25991
    [6] Kazi M, Annapure US (2016) Bacteriophage biocontrol of foodborne pathogens. J Food Sci Technol 53: 1355–1362. doi: 10.1007/s13197-015-1996-8
    [7] Gilmore BF (2012) Bacteriophages as anti-infective agents: recent developments and regulatory challenges. Expert Rev Anti Infe Ther 10: 533–535. doi: 10.1586/eri.12.30
    [8] Fernández L, Gutiérrez D, Rodríguez A, et al. (2018) Application of bacteriophages in the agro-food sector: a long way toward approval. Front Cell Infect Microbiol 8: 1–5. doi: 10.3389/fcimb.2018.00001
    [9] Balogh B, Jones JB, Iriarte FB (2010) Phage therapy for plant disease control. Curr Pharm Biotechno 11: 48–57. doi: 10.2174/138920110790725302
    [10] Civerolo EL, Kiel HL (1969) Inhibition of bacterial spot of peach foliage by Xanthomonas pruni bacteriophage. Phytopathology 59: 1966–1967.
    [11] Eman OH, El-Meneisy Afaf ZA (2014) Biocontrol of halo blight of bean caused by pseudomonas phaseolicola. Int J Virol 10: 235–242. doi: 10.3923/ijv.2014.235.242
    [12] Fujiwara A, Fujisawa M, Hamasaki R, et al. (2011) Biocontrol of ralstonia solanacearum by treatment with lytic bacteriophages. Appl Environ Microbiol 77: 4155–4162. doi: 10.1128/AEM.02847-10
    [13] Born Y, Bosshard L, Duffy B, et al. (2015) Protection of Erwinia amylovora bacteriophage Y2 from UV-induced damage by natural compounds. Bacteriophage 5: 1–5.
    [14] Zaccardelli M, Saccardi A, Gambin E (1992) Xanthomonas campestris pv. pruni bacteriophages on peach trees and their potential use for biological control. Plant Pathogenic Bacteria 8th International Conference 875–878.
    [15] Balogh B, Canteros BI, Stall RE (2008) Control of citrus canker and citrus bacterial spot with bacteriophages. Plant Dis 92: 1048–1052. doi: 10.1094/PDIS-92-7-1048
    [16] Balogh B, Jones JB, Iriarte FB (2010) Phage therapy for plant disease control. Curr Pharm Biotechno 11: 48–57. doi: 10.2174/138920110790725302
    [17] Leverentz B, Conway WS, Alavidze Z (2001) Examination of bacteriophage as a biocontrol method for Salmonella on fresh-cut fruit: a model study. J Food Protect 64: 1116–1121. doi: 10.4315/0362-028X-64.8.1116
    [18] Szczepankowska A (2012) Role of CRISPR/cas system in the development of bacteriophage resistance. Adv Virus Res 82: 289–338. doi: 10.1016/B978-0-12-394621-8.00011-X
    [19] Koskella B, Brockhurs MA (2014) Bacteria–phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev 38: 916–931. doi: 10.1111/1574-6976.12072
    [20] Carrillo LC, Atterbury JR, El-Shibiny A (2005) Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microb 71: 6554–6563. doi: 10.1128/AEM.71.11.6554-6563.2005
    [21] Wagenaar AJ, Van Bergen M, Mueller M (2005) Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol 109: 275–283. doi: 10.1016/j.vetmic.2005.06.002
    [22] Arthur MT, Kalchayanand N, Agga EG, et al. (2017) Evaluation of bacteriophage application to cattle in lairage at beef processing plants to reduce Escherichia coli O157:H7. Prevalence on hides and carcasses. Foodborne Pathog Dis 14: 17–22. doi: 10.1089/fpd.2016.2189
    [23] Wall KS, Zhang J, Rostagno HM (2010) Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microb 76: 48–53. doi: 10.1128/AEM.00785-09
    [24] Bach JS, Johnson PR, Stanford K (2009) Bacteriophages reduce Escherichia coli O157:H7 levels in experimentally inoculated sheep. Can J Animal Sci 89: 285–293. doi: 10.4141/CJAS08083
    [25] Huanga K, Nitin N (2019) Edible bacteriophage based antimicrobial coating on fish feed for enhanced treatment of bacterial infections in aquaculture industry. Aquaculture 502: 18–25 doi: 10.1016/j.aquaculture.2018.12.026
    [26] Rivas L, Coffey B, McAuliffe O (2010) In vivo and ex vivo evaluations of bacteriophages e11/2 and e4/1c for use in the control of Escherichia coli O157:H7. App Environ Microb 76: 7210–7216. doi: 10.1128/AEM.01530-10
    [27] Hussain MA, Liu H, Wang Q (2017) Use of encapsulated bacteriophages to enhance farm to fork food safety. Crit Rev Food Sci 57: 2801–2810. doi: 10.1080/10408398.2015.1069729
    [28] Murthy K, Engelhardt R (2012) Encapsulated bacteriophage formulation. United States Patent 2012/0258175 A1. 2012-10-11.
    [29] Stanford K, Mcallister AT, Niu DY (2010) Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in Feedlot Cattle. J Food Protect 73: 1304–1312. doi: 10.4315/0362-028X-73.7.1304
    [30] Saez AC, Zhang J, Rostagno MH, et al. (2011) Direct feeding of microencapsulated bacteriophages to reduce Salmonella colonization in pigs. Foodborne Pathog Dis 8: 1241–1248. doi: 10.1089/fpd.2011.0868
    [31] Ma Y, Pacan CJ, Wang Q (2008) Microencapsulation of bacteriophage felix O1 into chitosan- alginate microspheres for oral delivery. Appl Environ Microb 74: 4799–4805. doi: 10.1128/AEM.00246-08
    [32] EFSA (European Food Safety Authority), ECDC (European Centre for Disease Prevention and Control) (2017) The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2016. EFSA J 15: 5077.
    [33] Word Health Organzation (2019) Food safety. Available from: https://www.who.int/news-room/fact-sheets/detail/food-safety.
    [34] Moye ZD, Woolstone J, Sulakvelidze A (2018) Bacteriophage Applications for Food Production and Processing. Viruses 10: 1–22.
    [35] Endersen L, O'Mahony J, Hill C, et al. (2014) Phage Therapy in the Food Industry. Annu. Rev Food Sci Technol 5: 327–349. doi: 10.1146/annurev-food-030713-092415
    [36] de Melo AG, Levesque S, Moineau S (2018) Phages as friends and enemies in food processing. Curr Opin Biotechnol 49: 185–190. doi: 10.1016/j.copbio.2017.09.004
    [37] Atterbury RJ, Connerton PL, Dodd CE, et al. (2003) Application of host-specific bacteriophages to the surface of chicken skin leads to a reduction in recovery of Campylobacter jejuni. Appl Environ Microb 69: 6302–6306. doi: 10.1128/AEM.69.10.6302-6306.2003
    [38] Goode D, Allen VM, Barrow PA (2003) Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages. Appl Environ Microb 69: 5032–5036. doi: 10.1128/AEM.69.8.5032-5036.2003
    [39] Bigwood T, Hudson JA, Billington C (2009) Influence of host and bacteriophage concentrations on the inactivation of food-borne pathogenic bacteria by two phages. FEMS Microbiol Lett 291: 59–64. doi: 10.1111/j.1574-6968.2008.01435.x
    [40] Orquera S, Golz G, Hertwig S, et al. (2012) Control of Campylobacter spp. and Yersinia enterocolitica by virulent bacteriophages. J Mol Genet Med 6: 273–278.
    [41] O'Flynn G, Ross RP, Fitzgerald GF, et al. (2004) Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl Environ Microb 70: 3417–3424. doi: 10.1128/AEM.70.6.3417-3424.2004
    [42] Abuladze T, Li M, Menetrez MY, et al. (2008) Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl Environ Microb 74: 6230–6238. doi: 10.1128/AEM.01465-08
    [43] Sharma M, Patel JR, Conway WS, et al. (2009) Effectiveness of bacteriophages in reducing Escherichia coli O157:H7 on fresh-cut cantaloupe and lettuce. J Food Prot 72: 1481–1485. doi: 10.4315/0362-028X-72.7.1481
    [44] Carter CD, Parks A, Abuladze T, et al. (2012) Bacteriophage cocktail significantly reduced Escherichia coli O157H:7contamination of lettuce and beef, but does not protect against recontamination. Bacteriophage 2: 178–185. doi: 10.4161/bact.22825
    [45] Boyacioglu O, Sharma M, Sulakvelidze A, et al. (2013) Biocontrol of Escherichia coli O157: H7 on fresh-cut leafy greens. Bacteriophage 3: 1–6.
    [46] Viazis S, Akhtar M, Feirtag J, et al. (2011) Reduction of Escherichia coli O157:H7 viability on leafy green vegetables by treatment with a bacteriophage mixture and trans-cinnamaldehyde. Food Microbiol 28: 149–157.
    [47] Patel J, Sharma M, Millner P, et al. (2011) Inactivation of Escherichia coli O157:H7 attached to spinach harvester blade using bacteriophage. Foodborne Pathog Dis 8: 541–546. doi: 10.1089/fpd.2010.0734
    [48] Carlton RM, Noordman WH, Biswas B, et al. (2005) Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharm 43: 301–312. doi: 10.1016/j.yrtph.2005.08.005
    [49] Holck A, Berg J (2009) Inhibition of Listeria monocytogenes in cooked ham by virulent bacteriophages and protective cultures. Appl Environ Microbiol 75: 6944–6946 . doi: 10.1128/AEM.00926-09
    [50] Soni KA, Nannapaneni R., Hagens S (2010) Reduction of Listeria monocytogenes on the surface of fresh channel catfish fillets by bacteriophage listex p100. Foodborne Pathog Dis 7: 427–434 . doi: 10.1089/fpd.2009.0432
    [51] Soni KA, Desai M, Oladunjoye A, et al. (2012) Reduction of Listeria monocytogenes in queso fresco cheese by a combination of listericidal and listeriostatic GRAS antimicrobials. Int J Food Microbiol 155: 82–88. doi: 10.1016/j.ijfoodmicro.2012.01.010
    [52] Chibeu A, Agius L, Gao A, et al. (2013) Efficacy of bacteriophage LISTEXTM P100 combined with chemical antimicrobials in reducing Listeria monocytogenes in cooked turkey and roast beef. Int J Food Microbiol 167: 208–214. doi: 10.1016/j.ijfoodmicro.2013.08.018
    [53] Figueiredo ACL, Almeida RCC (2017) Antibacterial efficacy of nisin, bacteriophage P100 and sodium lactate against Listeria monocytogenes in ready-to-eat sliced pork ham. Braz J Microbiol 48: 724–729. doi: 10.1016/j.bjm.2017.02.010
    [54] Guenther S, Loessner MJ (2011) Bacteriophage biocontrol of Listeria monocytogenes on soft ripened white mold and red-smear cheeses. Bacteriophage 1: 94–100. doi: 10.4161/bact.1.2.15662
    [55] Bigot B, Lee WJ, McIntyre L, et al. (2011) Control of Listeria monocytogenes growth in a ready-to-eat poultry product using a bacteriophage. Food Microbiol 28: 1448–1452. doi: 10.1016/j.fm.2011.07.001
    [56] Modi R, Hirvi Y, Hill A, et al. (2001) Effect of phage on survival of Salmonella Enteritidis during manufacture and storage of cheddar cheese made from raw and pasteurized milk. J Food Protect 64: 927–933. doi: 10.4315/0362-028X-64.7.927
    [57] Leverentz B, Conway WS, Camp MJ, et al. (2003) Biocontrol of Listeria monocytogenes on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. Appl Environ Microbiol 69: 4519–4526. doi: 10.1128/AEM.69.8.4519-4526.2003
    [58] Whichard JM, Sriranganathan N, Pierson FW, et al. (2003) Suppression of Salmonella growth by wild-type and large-plaque variants of bacteriophage Felix O1 in liquid culture and on chicken frankfurters. J Food Prot 66: 220–225. doi: 10.4315/0362-028X-66.2.220
    [59] Guenther S, Herzig O, Fieseler L, et al. (2012) Biocontrol of Salmonella Typhimurium in RTE foods with the virulent bacteriophage FO1-E2. Int J Food Microbiol 154: 66–72. doi: 10.1016/j.ijfoodmicro.2011.12.023
    [60] Spricigo DA, Bardina C, Cortés P, et al. (2013) Use of a bacteriophage cocktail to control Salmonella in food and the food industry. Int J Food Microbiol 165: 169–174. doi: 10.1016/j.ijfoodmicro.2013.05.009
    [61] Farber JM, Peterkin PI (1991) Listeria monocytogenes, a foodborne pathogen. Microbiol Rev 55: 476–511.
    [62] Leistner L, Gorris LGM (1995) Food preservation by hurdle technology. Trends Food Sci Technol 6: 41–46 . doi: 10.1016/S0924-2244(00)88941-4
    [63] Phages as probiotics. Available from: http://intralytix.com/index.php?page=pro.
    [64] Proteon Pharmaceuticals. Available from: https://www.proteonpharma.com.
    [65] Schmelcher M, Loessner JM (2016) Bacteriophage endolysins: applications for food safety. Curr Opin Biotechnol 37: 76–87. doi: 10.1016/j.copbio.2015.10.005
    [66] Gutiérrez D, Rodríguez-Rubio L, Martíne B, et al. (2016) Bacteriophages as weapons against bacterial biofilms in the food industry. Front Microbiol 7: 1–16.
    [67] Da Silva Felício MT, Hald T, Liebana E, et al. (2015) Risk ranking of pathogens in ready-to-eat unprocessed foods of non-animal origin (FoNAO) in the EU: initial evaluation using outbreak data (2007–2011). Int J Food Microbiol 16: 9–19.
    [68] Beuchat LR (2002) Ecological factors influencing survival and growth of human pathogens on raw fruits and vegetables. Microbes Infect 4: 413–423. doi: 10.1016/S1286-4579(02)01555-1
    [69] Siringan P, Connerton PL, Payne RJ (2011) Bacteriophage-mediated dispersal of Campylobacter jejuni biofilms. Appl Environ Microb 77: 3320–3326. doi: 10.1128/AEM.02704-10
    [70] Soni KA, Nannapaneni R, Hagens S (2010) Reduction of Listeria monocytogenes on the surface of fresh channel catfish fillets by bacteriophage listex p100. Foodborne Pathog Dis 7: 427–434. doi: 10.1089/fpd.2009.0432
    [71] Sutherland IW, Hughes KA, Skillman LC, et al. (2004) The interaction of phage and biofilms. FEMS Microbiol Lett 232: 1–6. doi: 10.1016/S0378-1097(04)00041-2
    [72] Maszewska A (2015) Phage associated polysaccharide depolymerases–characteristics and application. Postep Hig Med Dos 69: 690–702. doi: 10.5604/17322693.1157422
    [73] Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B (2015) Bacteriophages and phage- derived proteins--application approaches. Curr Med Chem 22: 1757–1773. doi: 10.2174/0929867322666150209152851
    [74] Lehman SM (2007) Development of a bacteriophage-based biopesticide for fire blight. PhD Thesis. Department of Biological Sciences, Brock University, Canada.
    [75] Hughes KA, Sutherland IW, Jones MV (1998) Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 144: 3039–3047. doi: 10.1099/00221287-144-11-3039
    [76] Chai Z, Wang J, Tao S, et al. (2014) Application of bacteriophage-borne enzyme combined with chlorine dioxide on controlling bacterial biofilm. LWT Food Sci Technol 59: 1159–1165. doi: 10.1016/j.lwt.2014.06.033
    [77] Love JM, Bhandari D, Dobson CR, et al. (2018) Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care. Antibiotics 7: 1–25.
    [78] Gutierrez D, Ruas-Madiedo P, Martınez B (2014) Effective removal of Staphylococcal biofilms by the endolysin LysH5. PloS One 9: 1–8.
    [79] Oliveira H, Thiagarajan V, Walmagh M (2014) A thermostable Salmonella phage endolysin Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PloS One 9: 1–11.
    [80] Obeso MJ, Martínez B, Rodríguez A, et al. (2008) Lytic activity of the recombinant staphylococcal bacteriophage ΦH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 128: 212–218. doi: 10.1016/j.ijfoodmicro.2008.08.010
    [81] Olsen NMC, Thiran E, Hasler T, et al. (2018) Synergistic removal of static and dynamic Staphylococcus aureus biofilms by combined treatment with a bacteriophage endolysin and a polysaccharide depolymerase. Viruses 10: 2–17.
    [82] Yoyeon Ch, Son B, Ryu S (2019) Effective removal of staphylococcal biofilms on various food contact surfaces by Staphylococcus aureus phage endolysin LysCSA13. Food Microbiol 84: 1–7.
    [83] Zhang H, Bao H, Billington C (2012) Isolation and lytic activity of the Listeria bacteriophage endolysin LysZ5 against Listeria monocytogenes in soya milk. Food Microbiol 31: 133–136. doi: 10.1016/j.fm.2012.01.005
    [84] Van Nassau TJ, Lenz CA, Scherzinger AS (2017) Combination of endolysins and high pressure to inactivate Listeria monocytogenes. Food Microbiol 68: 81–88. doi: 10.1016/j.fm.2017.06.005
    [85] Gaeng S, Scherer S, Neve H (2000) Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Appl Environ Microb 66: 2951–2958. doi: 10.1128/AEM.66.7.2951-2958.2000
    [86] Garneau EJ, Moineau S (2001) Bacteriophages of lactic acid bacteria and their impact on milk fermentations. Microb Cell Fact 10: 1–10.
    [87] Atamer Z, Samtlebe M, Neve H, et al. (2013) Review: elimination of bacteriophages in whey and whey products. Front Microbiol 4: 1–9.
    [88] Mercanti D, Carminati D, Reinheimer JA, et al. (2011) Widely distributed lysogeny in probiotic lactobacilli represents a potentially high risk for the fermentative dairy industry. Int J Food Microbiol 144: 503–510. doi: 10.1016/j.ijfoodmicro.2010.11.009
    [89] Tahir A, Asif M, Abbas Z (2017) Three bacteriophages SA, SA2 and SNAF can control growth of milk isolated Staphylococcal species. Pak J Zool 49: 425–759. doi: 10.17582/journal.pjz/2017.49.2.425.434
    [90] Singh A, Poshtiban S, Evoy S (2013) Recent advances in bacteriophage based biosensors for food-borne pathogen detection. Sensors 13: 1763–1786. doi: 10.3390/s130201763
  • This article has been cited by:

    1. Anrea Di Schino, Marco Corradi, Construction and building materials, 2020, 7, 2372-0484, 157, 10.3934/matersci.2020.2.157
    2. Grzegorz Ludwik Golewski, Fracture Performance of Cementitious Composites Based on Quaternary Blended Cements, 2022, 15, 1996-1944, 6023, 10.3390/ma15176023
    3. Nan Yao, Xiaocheng Zhou, Yongqi Liu, Jinjie Shi, Synergistic effect of red mud and fly ash on passivation and corrosion resistance of 304 stainless steel in alkaline concrete pore solutions, 2022, 132, 09589465, 104637, 10.1016/j.cemconcomp.2022.104637
    4. Ernesto Mora, Erick Castellón, The role of coarse aggregates in hydrophobized hydraulic concrete, 2022, 11, 2046-0147, 209, 10.1680/jemmr.21.00027
    5. Grzegorz Ludwik Golewski, Mechanical properties and brittleness of concrete made by combined fly ash, silica fume and nanosilica with ordinary Portland cement, 2023, 10, 2372-0484, 390, 10.3934/matersci.2023021
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(11894) PDF downloads(1508) Cited by(122)

Figures and Tables

Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog